降钙素基因相关肽（CGRP）受体的纯化和鉴定

降钙素基因相关肽（ＣＧＲＰ）为３７肽,它在体内主要分布于神经系统和心血管系统,是较强的扩张血管物质,人们已认识到脑部的ＣＧＲＰ最多,由于鹇猪脑来源丰富,故我们选用猪脑为材料来纯化ＣＧＲＰ受体。以期为该受体的深入研究提供足够的材料和奠定基础,纯化的受体将用于制备抗ＣＧＲＰ受体的单克隆抗体。为了从猪脑中纯化ＣＲＲＰ受体,首先用含有胆盐的磷酸盐缓冲液将该受体从猪脑细胞膜上解离下来,解离下来的受体量较多,     

降钙素受体刺激肽：降钙素基因相关肽家族的新成员

降钙素基因相关肽 (ｃａｌｃｉｔｏｎｉｎ ｇｅｎｅｒｅｌａｔｅｄｐｅｐｔｉｄｅ ,ＣＧＲＰ)家族包括五个成员 :降钙素 (Ｃａｌｃｉｔｏｎｉｎ ,ＣＴ)、胰淀粉样酶 (Ａｍｙｌｉｎ)、两种降钙素基因相关肽和肾上腺髓质素 (ａｄｒｅｎｏｍｅｄｕｌｌｉｎ ,ＡＤＭ)。ＣＧＲＰ和其受体在体内广泛分布 ,是目前已知最强的内源性扩血管肽 ;ＣＴ主要参与体内的钙代谢 ;Ａｍｙｌｉｎ位于胰腺的 β细胞 ,可能与Ⅱ型糖尿病有关 ;ＡＤＭ的生物学作用与ＣＧＲＰ相似 ,亦具有强的扩血管作用。ＫａｔａｆｕｃｈｉＴ等将在 2 0 0 3年的ＪＢｉｏｌＣｈｅｍ杂…     

人食管鳞状上皮癌糖复合物表达的研究

凝集素可与其相对应的糖复合物特异性结合。在癌症形成过程中细胞表面经历着显著的变化,本文用十种生物素化凝集素即ＵＥＡ－Ｉ、ＲＣＡ－Ｉ、ＤＢＡ、ＰＳＡ、ＰＮＡ、ＢＳＬ、ＬＣＡ、ＷＧＡ、ＣｏｎＡ和ＳＢＡ作为探针,对正常食管上皮和食管鳞状上皮癌进行研究,以确定正常食管上皮和食管鳞状上皮癌中糖复合物的改变,结果发现,ＰＮＡ和ＰＳＡ在正常食管和食管鳞状上皮癌中均无反应,ＲＣＡ－Ｉ、ＤＢＡ、ＢＳＬ、ＬＣＡ、ＣｏｎＡ和ＳＢＡ受体在正常和癌组织中有着特征性变化,ＢＳＬ和ＤＢＡ在食管中无反应,ＬＣＡ、ＳＢＡ和ＲＣＡ－１正常食管和食管鳞状上皮癌中反应方式不同,ＣｏｎＡ和ＷＧＡ则在同一癌组织的不同部位都显示出不同的反应。尽管ＵＥＡ－Ｉ在正常食管和食管鳞状上皮癌均呈阳性反应,但似乎未表现出有意义的变化。上述结果提示食管癌的发生与含α－Ｄ－ＧａｌＮＡｃ（ＤＢＡ和ＳＢＡ）、β－Ｄ－Ｇａｌ／β－Ｎ－ａｃｅｔｙｌ－Ｄ－Ｇａｌａｃｔｏｓａｍｉｎｅ（ＲＣＡ－Ｉ）、α－Ｄ－Ｇｌｃ／α－Ｄ－Ｍａｎ（ＬＣＡ和ＣｏｎＡ）、［β－（１－４）－Ｄ－ＧｌｃＮＡｃ］２／ＮｅｕＮＡｃ（ＷＧＡ）和α－Ｄ－Ｇａｌ（ＢＳＬ）等的糖复合物的改变有较为密切的关系。     

蛇毒蛋白Echistatin的C端突变基因的构建,表达及其活性研究

通过ＰＣＲ定点突变的技术,将蛇毒蛋白Ｅｃｈｉｓｔａｔｉｎ基因的Ｃ端进行了突变（Ａｌａ４８→Ａｒｇ４８→,Ｔｈｒ４９→Ｖａｌ４９）,模拟纤维蛋白Ｎ端的四肽（Ｇｌｙ－Ｐｒｏ－Ａｒｇ－Ｖａｌ）,以期增加Ｅｃｓ（Ｅｃｈｉｓｔａｔｉｎ）的活性,突变的基因重组到表达质粒ｐＪＣ２６４上,经ＩＰＴＧ诱导,以ＣｈｅＹ－Ｅｃｓ融合蛋白方式进行了表达,表达量占菌体总蛋白的１５￣２０％,Ｓｅｐｈａｄｅｘ Ｇ－７５初步纯化     

小鼠颌下腺降钙素基因相关肽的免疫组织化学定位

本文用免疫组织化学ＡＢＣ法,对小鼠颌下腺中降钙素基因相关肽（ＣａｌｃｉｔｏｎｉｃＧｅｎｅ－ＲｅｌａｔｅｄＰｅｐｔｉｄｅ,ＣＧＲＰ）的分布进行了观察。结果表明：小鼠颌小腔内有降钙素基因相关肽免疫反应神经的分布,它们主要分布于小叶间结缔组织中。此外,颗粒由管细胞也呈降钙素基因相关肽免疫反应阳性。提示降钙素基因相关肽可能参与颌下腺的分泌活动及血液循环等生理调节。     

Gi和Go的同时纯化及其性质研究

经ＤＥＡＥ－Ｓｅｐｈａｃｅｌ、ＵｌｔｒｏｇｅｌＡｃＡ ３４、Ｈｅｐｔｙｌａｍ ｉｎｅ－Ｓｅｐｈａｒｏｓｅ 和Ｂｉｏ Ｓｃａｌｅ Ｑ２等四步层析从牛脑皮层膜中同时纯化出抑制型Ｇ 蛋白（ｉｎｈｉｂｉｔｏｒｙ Ｇ ｐｒｏｔｅｉｎ, Ｇｉ）和Ｏ型Ｇ蛋白（ｏｔｈｅｒ Ｇ ｐｒｏ－ｔｅｉｎ, Ｇｏ）．对Ｇｏ 的选择性激活使Ｇｉ 和Ｇｏ 的分离大为简化,并使二者的大量制备成为可能．纯化的Ｇ 蛋白的ＳＤＳ－ＰＡＧＥ银染显示单一蛋白带,其结合［３５Ｓ］ＧＴＰγＳ的活性分别提高６８倍和１２４倍．用圆二色光谱法（ＣＤ）测量了纯化的Ｇ蛋白的二级结构．     

大鼠鼻粘膜肽能神经末梢分布的研究

用免疫组化技术（ＡＢＣ法）系统研究了大鼠鼻粘膜９种肽能神经末梢分布的特征,这９种神经肽分别是Ｐ物质（ｓｕｂｓｔａｎｃｅＰ,ＳＰ）,神经激肽Ａ（ｎｅｕｒｏｋｉｎｉｎＡ,ＮＫＡ）,神经激肽Ｂ（ｎｅｕｒｏｋｉｎｉｎＢ,ＮＫＢ）,降钙素基因相关肽（ｃａｌｃｉｔｏｎｉｎｇｅｎｅ－ｒｅｌａｔｅｄｐｅｐｔｉｄｅ,ＣＧＲＰ）,血管活性肠多肽（ｖａｓｏａｃｔｉｖｅｉｎｔｅｓｔｉｎａｌｐｏｌｙｐｅｐｔｉｄｅ,ＶＩＰ）,神经肽Ｙ（ｎｅｕｒｏｐｅｐｔｉｄｅＹ,ＮＰＹ）,甘丙肽（ｇａｌａｎｉｎ,ＧＡＬ）,生长抑素（ｓｏｍａｔｏｓｔａｔｉｎ,ＳＯＭ）及神经降压素（ｎｅｕｒｏｔｅｎｓｉｎ,ＮＴ）,同时选择与鼻粘膜神经肽（ＮＰ）作用密切相关的三叉神经节（ＴＧ）细胞进行上述ＮＰ的定位。用重组ＰＳＰ６５质粒（４００ＳＯＭｃＤＮＡ）制备ＳＯＭｍＲＮＡ单链探针,以地高辛精标记,在鼻粘膜及ＴＧ细胞进行ＳＯＭｍＲＮＡ的原位杂交组化研究。结果提示大鼠鼻粘膜有丰富的肽能神经末梢;ＴＧ细胞含有多种ＮＰ并且可以合成ＳＯＭ。该研究结果对重新认识鼻粘膜神经分布规律有一定意义。     

蛇毒蛋白Echistatin的C端突变基因的构建，表达及其活性研究

通过ＰＣＲ定点突变的技术,将蛇毒蛋白Ｅｃｈｉｓｔａｔｉｎ基因的Ｃ端进行了突变（Ａｌａ４８→Ａｒｇ４８→,Ｔｈｒ４９→Ｖａｌ４９）,模拟纤维蛋白Ｎ端的四肽（Ｇｌｙ－Ｐｒｏ－Ａｒｇ－Ｖａｌ）,以期增加Ｅｃｓ（Ｅｃｈｉｓｔａｔｉｎ）的活性。突变的基因重组到表达质粒ｐＪＣ２６４上,经ＩＰＴＧ诱导,以ＣｈｅＹ－Ｅｃｓ融合蛋白方式进行了表达,表达量占菌体总蛋白的１５～２０％。ＳｅｐｈａｄｅｘＧ－７５初步纯化该融合蛋白,然后用ＣＮＢｒ裂解,透析,冻干,反相ＨＰＬＣ纯化Ｃ端突变体Ｅｃｓ蛇毒蛋白,Ｎ端十个氨基酸分析与天然的相符,在ＰＲＰ（ｐｌａｔｅｌｅｔ－ｒｉｃｈｐｌａｓｍａ）测活体系中,１０μｍｏｌ／Ｌ的ＡＤＰ诱导,Ｃ端突变体Ｅｃｓ抑制血小板凝聚的活性约为野生型４倍。得到了Ｅｃｓ的Ｃ端突变后使Ｅｃｓ抑制血小板凝聚的活性提高的结果。     

雄激素受体与雄激素应答元件的相互作用

将雄激素受体（ＡＲ）的ｃＤＮＡ１１１９ｂｐ片段（１１０５－２２２４）（其中包含其ＤＮＡ结合结构域到部分激素结合结构域）克隆于表达南粒ｐＧＥＸ中,通过ＩＰＴＧ诱地,在Ｅ．ｃｏｌｉ中表达ＧＳＴ－ＡＲ融合蛋白,经谷胱甘肽－Ｓｅｐｈａｒｏｓｅ－４Ｂ亲和层析得以部分纯化。利用一个有雄激素应答元件（ＡＲＥ）活性的Ｃ３（１）ＤＮＡ片段为阳性探针,通过凝胶阻滞分析和ＤＮａｓｅ１足迹法证明此表达产物具有牧民的ＤＮＡ     

王不留行环肽研究

从中药王不留行（Ｖａｃａｒｉａｓｅｇｅｔａｌｉｓ）种子中分离并鉴定了４个环肽化合物,分别命名为王不留行环肽Ａ,Ｂ,Ｃ,Ｄ（ｖａｃｃａｒｉｎｓＡ,Ｂ,Ｃ,Ｄ）,其中王不留行环肽Ａ为新环肽化合物。其结构通过光谱和化学方法分别确定为：ｖａｃｃａｒｉｎＡ——ｃｙｃｌｏ－（Ｔｒｐ－Ａｌａ１－Ｇｌｙ－Ｖａｌ－Ａｌａ２）,ｖａｃｃａｒｉｎＢ———ｃｙｃｌｏ－（Ｐｒｏ－Ｇｌｙ－Ｌｅｕ－Ｓｅｒ－Ｐｈｅ１－Ａｌａ－Ｐｈｅ２）,ｖａｃｃａｒｉｎＣ———ｃｙｃｌｏ－（Ｐｒｏ１－Ｇｌｙ－Ｔｙｒ－Ｖａｌ－Ｐｒｏ２－Ｌｅｕ－Ｔｒｐ）,ｖａｃａｒｉｎＤ———ｃｙｃｌｏ－（Ｐｒｏ－Ｖａｌ１－Ｔｒｐ－Ａｌａ－Ｇｌｙ－Ｖａｌ２）．     

Comparative affinities of adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) for [125I] AM and [125I] CGRP specific binding sites in porcine tissues.

We have investigated the binding characteristics of rat [125I] adrenomedullin (AM) and human [125I] calcitonin gene-related peptide (CGRP) to membranes prepared from a number of porcine tissues including atrium, ventricle, lung, spleen, liver, renal cortex and medulla. These membranes displayed specific, high affinity binding for [125I] rat AM and [125I] human CGRP. Porcine lung displayed the highest density of binding sites for radiolabeled AM and CGRP followed by porcine renal cortex. Competition experiments performed with [125I] rat AM indicated that the rank order of potencies of various peptides for inhibiting [125I] rat AM binding to various tissues were rat AM > or = human AM > or = human AM(22-52) > h alpha CGRP > or = h alpha CGRP(8-37) > sCT except spleen, atrium, renal cortex and renal medulla where rAM and hAM were 20-300 fold more potent than hAM (22-52). When the same experiments were performed using [125I] h alpha CGRP as the radioligand, the rank order potencies for various peptides were rAM = hAM > h alpha CGRP > h alpha CGRP(8-37) in most of the tissues except in spleen and liver where h alpha CGRP was the most potent ligand. In lung, h alpha CGRP was almost as potent as rAM and hAM in displacing [125I] h alpha CGRP binding. These data suggest the existence of distinct CGRP and AM specific binding sites in contrast to previous reports that showed that both peptides interact differently in rat tissues.     

Characterization of functional calcitonin gene-related peptide receptors on rat lymphocytes.

Calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide present in peripheral neurons, is released at local sites of inflammation. In these studies specific high affinity adenylyl cyclase linked CGRP receptors were characterized on rat lymphocytes. The distribution, affinity, and specificity of CGRP receptors was analyzed by radioligand binding. 125I-[His10]CGRP binding to rat lymphocytes was rapid, reaching equilibrium by 20 to 30 min at 22 degrees C, and dependent on cell concentration. The dissociation constants, Kd, for the CGRP receptor on purified T and B lymphocytes are 0.807 +/- 0.168 nM and 0.387 +/- 0.072 nM and the densities are 774 +/- 387 and 747 +/- 244 binding sites/cell, respectively. Competition binding studies determined that rat CGRP inhibits 125I-[His10]CGRP binding to lymphocytes with the highest affinity (Ki = 0.192 +/- 0.073) followed by human CGRP and the CGRP receptor antagonist CGRP8-37. 125I-[His10]CGRP binding to rat lymphocytes was not inhibited by the neuropeptides substance P, calcitonin, or neuropeptide Y. Lymphocyte CGRP receptor proteins were identified by affinity labeling by using disuccinimidyl suberate to covalently cross-link 125I-[His10]CGRP to its receptor. Specifically labeled CGRP binding proteins visualized by SDS-PAGE analysis had molecular masses of 74.5 and 220 kDa. A third high molecular mass protein band which did not penetrate the gel was also observed. In functional studies, CGRP stimulated a rapid, sustained increase in cAMP with an ED50 of approximately 8 pM. In experiments comparing optimal concentrations of isoproterenol, a beta 2-adrenergic agonist, and CGRP, intracellular cAMP elevation after isoproterenol treatment returned to basal levels by 30 min, whereas cAMP was still elevated at 60 min after CGRP treatment. The response to CGRP was specific in that it could be completely blocked by CGRP8-37. The presence of high affinity functional CGRP receptors on T and B lymphocytes provides evidence for a modulatory role for CGRP in regulating lymphocyte function.     

Proceedings of the 4th International Meeting on Calcitonin Gene-Related Peptide and its Receptor

Calcitonin Gene-Related Peptide (CGRP), a 37 amino acid peptide identified as the alternately spliced gene product of calcitonin gene, is a sensory neuropeptide with potent cardiovascular effects. CGRP is distributed throughout the central and peripheral nervous systems and possesses diverse biological actions. CGRP has been suggested to play a role in diseases such as migraine, diabetes, pain, and inflammation. Two forms of CGRP (alpha and beta) that differ in three amino acids have been identified and are encoded by different genes. Based on the differential biological activities of various CGRP analogs, the CGRP receptors have been classified into CGRP1 and CGRP2. Structure-activity studies of CGRP analogs showed that the C- and N-terminal regions of the peptide interact independently with their receptors. While C-terminal peptide, CGRP (8-37) behaves as a CGRP1 receptor antagonist, N-terminal peptide CGRP (1-12) behaves as a weak agonist. Structural modifications of CGRP(28-37) have yielded micromolar to nanomolar affinity ligands. CGRP receptor belongs to the calcitonin receptor like receptor (CRLR) family of G-protein-coupled receptors and has been shown to require a single transmembrane domain protein called receptor activity modifying protein-1 (RAMP1) for its functional expression as well as activity. Human, rat, and porcine CRLRs have been cloned and characterized. Currently, the major focus is on the identification of potent and specific nonpeptide antagonists for this receptor in order to understand the physiological and pathophysiological role of this peptide.     

Comparative Affinities of Adrenomedullin (AM) and Calcitonin Gene-Related Peptide (CGRP) for [125I] AM and [125I] CGRP Specific Binding Sites in Porcine Tissues

Abstract

We have investigated the binding characteristics of rat [¹²⁵I] adrenomedullin (AM) and human [¹²⁵I] calcitonin gene-related peptide (CGRP) to membranes prepared from a number of porcine tissues including atrium, ventricle, lung, spleen, liver, renal cortex and medulla. These membranes displayed specific, high affinity binding for [¹²⁵I] rat AM and [¹²⁵I] human CGRP. Porcine lung displayed the highest density of binding sites for radiolabeled AM and CGRP followed by porcine renal cortex. Competition experiments performed with [¹²⁵I] rat AM indicated that the rank order of potencies of various peptides for inhibiting [¹²⁵I] rat AM binding to various tissues were rat AM ≥ human AM ≥ human AM(22–52) > hαCGRP ≥ hαCGRP(8–37) <<<< sCT except spleen, atrium, renal cortex and renal medulla where rAM and hAM were 20–300 fold more potent than hAM(22–52). When the same experiments were performed using [¹²⁵I] hαCGRP as the radioligand, the rank order potencies for various peptides were rAM = hAM > hαCGRP > hαCGRP(8–37) in most of the tissues except in spleen and liver. where hαCGRP was the most potent ligand. In lung, hαCGRP was almost as potent as rAM and hAM in displacing [¹²⁵I] hαCGRP binding. These data suggest the existence of distinct CGRP and AM specific binding sites in contrast to previous reports that showed that both peptides interact differently in rat tissues.     

The pharmacology of CGRP-responsive receptors in cultured and transfected cells

Historically, CGRP receptors have been classified as CGRP(1) or CGRP(2) subtypes, chiefly depending on their affinity for the antagonist CGRP(8-37). It has been shown that the complex between calcitonin receptor-like receptor (CRLR or CL) and receptor activity modifying protein (RAMP) 1 provides a molecular correlate for the CGRP(1) receptor; however, this does not explain the range of affinities seen for CGRP(8-37) in isolated tissues. It is suggested that these may largely be explained by a combination of methodological factors and CGRP-responsive receptors generated by CL and RAMP2 or RAMP3 and complexes of RAMPs with the calcitonin receptor.     

Differential Calcitonin Gene-Related Peptide (CGRP) and Amylin Binding Sites in Nucleus Accumbens and Lung: Potential Models for Studying CGRP/Amylin Receptor Subtypes

Abstract: Calcitonin gene-related peptide (CGRP), a 37-amino-acid peptide, is a member of a small family of peptides including amylin or islet amyloid polypeptide and salmon calcitonin. These related peptides have been shown to display similar effects on in vitro and in vivo carbohydrate metabolism. The present study was initiated to identify and characterize the binding sites for these peptides in lung and nucleus accumbens membranes prepared from pig and guinea pig. Both tissues in either species displayed high-affinity (2-[¹²⁵I]iodohistidyl¹⁰)humanCGRPα ([¹²⁵I]hCGRPα) binding (IC₅₀ = 0.4–7.7 nM), which was displaced by hCGRP_8–37α with equally high affinity (IC₅₀ = 0.4–7.3 nM). High-affinity binding for [¹²⁵I]Bolton-Hunter human amylin ([¹²⁵I]BH-h-amylin) was also observed in these tissues (IC₅₀ = 0.2–6.0 nM). In membranes from the nucleus accumbens of both species, salmon calcitonin competed for amylin binding sites with high affinity (IC₅₀ = 0.1 nM) but was poor in competing for amylin binding in lung membranes. Rat amylin_8–37 competed for [¹²⁵I]hCGRPα binding with higher affinity (IC₅₀ = 5.4 nM) compared with [¹²⁵I]BH-h-amylin binding (IC₅₀ = 200 nM) in porcine nucleus accumbens, whereas in guinea pig nucleus accumbens, the IC₅₀ values for rat amylin_8–37 were 117 and 12 nM against [¹²⁵I]hCGRPα and [¹²⁵I]BH-h-amylin, respectively. Also, functional studies evaluating the activation of adenylate cyclase and generation of cyclic AMP in response to these agonists indicated that hCGRPα (EC₅₀ = 0.3 nM), h-amylin (EC₅₀ = 150 nM), and salmon calcitonin (EC₅₀ = 1,000 nM) activated adenylate cyclase, resulting in increased cyclic AMP production in porcine lung membranes that was antagonized by hCGRP_8–37α. The affinity of hCGRP_8–37α was similar for all three peptides. The cyclic AMP responses to amylin and salmon calcitonin were significantly (p < 0.05) lower than that of hCGRPα and not additive, suggesting that they are acting as partial agonists at the same CGRP1-type receptor in porcine lung membranes. Similar observations were made for guinea pig lung membranes. However, human amylin and salmon calcitonin were weaker than hCGRPα in activating lung adenylate cyclase. None of these peptides activated adenylate cyclase in membranes prepared from the nucleus accumbens of both species. The data from these studies demonstrate both species and tissue differences in the existence of distinct CGRP and amylin binding sites and present a potential opportunity to study further CGRP and amylin receptor subtypes.     

降钙素基因相关肽家族受体及其受体活性修饰蛋白

降钙素基因相关肽家族是一类多功能的激素家族 ,参与人体的多种生物学功能 ,与多种疾病有关。降钙素基因相关肽受体包括降钙素受体 (CTR)和降钙素受体样受体 (CRLR) ,CTR可以独自与降钙素结合 ,而CRLR必须与一组称作受体活性修饰蛋白 (RAMPs)的蛋白质共同作用才能发挥生物学功能。综述CTR的研究概况及CRLR与RAMPs相互作用的机制和表达调控 ,以期为人们设计新型药物提供参考。     

Biochemical Evidence for the Existence of a Pool of Unassembled C2 Exon-Containing NR1 Subunits of the Mammalian Forebrain NMDA Receptor

Abstract: Optimum conditions were determined for the solubilisation of native NMDA receptors of adult mammalian brain with the retention of [³H]MK-801 radioligand binding activity. The most efficient conditions were 1% Triton X-100/1 M NaCl. The efficiency of solubilisation was as follows: cloned NMDA receptors expressed in mammalian cells > forebrain receptors > cerebellar receptors. Triton X-100/1 M NaCl-solubilised forebrain NMDA receptors had a molecular size of 710,000 daltons, but significant NR1 immunoreactivity (41%) migrated as a monomer of 125,000 daltons. Immunoaffinity purification of NMDA receptors from forebrain by anti-NR1 911–920 antibody affinity chromatography from 1% Triton X-100/1 M NaCl solubilised extracts yielded purification of the NR1 M_r 120,000 immunoreactive species, but no detectable NR2A or NR2B immunoreactivity. Immunoprecipitation of NMDA receptors from Triton X-100/1 M NaCl extracts with anti-NR1 911–920 antibodies also resulted in precipitation of NR1 subunits, but with no detectable NR2A or NR2B subunits. In contrast, by immunoprecipitation with anti-NR1 17–35 antibodies, which recognise all forms of NR1, NR1, NR2A, and NR2B immunoreactivities were detected in the immune pellets. Similarly, a coassociation of NR1, NR2A, and NR2B subunits was demonstrated following extraction of forebrain membranes with 1% sodium deoxycholate (pH 9) and purification by anti-NR1 911–920 antibody affinity chromatography. These results are consistent with the identification of a pool of unassembled C2 exon-containing NR1 subunits, i.e., NR1-1a, NR1-1b, NR1-2a, and NR1-2b, selectively solubilised by 1% Triton X-100/1 M NaCl.     

Affinity chromatography of the muscarinic acetylcholine receptor

A novel compound, 3-(2'-aminobenzhydryloxy)-tropane (ABT), and an ABT-agarose gel were synthesized and used for the purification of solubilized muscarinic receptors. ABT had a high affinity with an apparent dissociation constant (Kd) of 7 nM for the muscarinic receptors solubilized from the porcine brain by digitonin. An ABT-agarose gel was prepared by coupling ABT with epoxy-activated Sepharose 6B, and the degree of substitution to the gel was determined to be 4-5 mumol/ml of the gel by UV absorption spectrum. During affinity chromatography using 10 ml of the ABT-agarose gel and 100 ml of the digitonin-solubilized preparation, 70% of muscarinic receptors were adsorbed to the gel, in marked contrast with the adsorption of only 2% of proteins. Approximately 25% of muscarinic receptors applied to the gel were eluted biospecifically with 1 mM muscarinic ligands. The purified fraction showed a high affinity for [3H]quinuclidinyl benzylate with a Kd of 0.4 nM and similar specificity for muscarinic ligands to that of unpurified soluble receptors. The protein concentration of the purified fraction was too low to be determined accurately, but very approximately a purification of 10(3)-fold was indicated.     

Activities of calcitonin gene-related peptide (CGRP) and related peptides at the CGRP receptor.

In guinea pig pancreatic acini rat calcitonin gene-related peptide (CGRP) increased amylase release 2-fold, salmon calcitonin had an efficacy of only 44% of that of CGRP and [Tyr0]CGRP(28-37) and human calcitonin had no actions. [Tyr0]CGRP(28-37), but not human calcitonin, antagonized the actions of CGRP in pancreatic acini with an IC50 of 3 microM. [Tyr0]CGRP(28-37) produced a parallel rightward shift in the dose-response curve for CGRP-stimulated amylase secretion. The inhibition was specific for CGRP and was reversible. Studies with 125I-CGRP demonstrated that CGRP, salmon calcitonin and [Tyr0]CGRP, but not human calcitonin, interacted with CGRP receptors on pancreatic acini. These results indicate that various CGRP-related peptides demonstrate different relationships between their abilities to occupy the CGRP receptor and to affect biologic activity, with CGRP itself being a full agonist, salmon calcitonin a partial agonist, [Tyr0]CGRP(28-37) a competitive antagonist, and human calcitonin having no actions.